150 related articles for article (PubMed ID: 29068574)
1. Total antioxidant capacity in Mediterranean β-thalassemic patients.
Tsamesidis I; Fozza C; Vagdatli E; Kalpaka A; Cirotto C; Pau MC; Pantaleo A; Turrini F; Grigoriou E; Lymperaki E
Adv Clin Exp Med; 2017 Aug; 26(5):789-793. PubMed ID: 29068574
[TBL] [Abstract][Full Text] [Related]
2. Coenzyme Q10 levels in β-thalassemia and its association with ferritin levels and chelation therapy.
Karakukcu C; Karakukcu M; Unal E; Patiroglu T; Ozdemir MA; Torun YA; Tang PH
Hemoglobin; 2012; 36(3):219-29. PubMed ID: 22483337
[TBL] [Abstract][Full Text] [Related]
3. Chelation therapy with desferrioxamine does not normalize ferritin level but attenuates oxidative damage and improves total antioxidant level in Malaysian Chinese beta-thalassaemia major patients.
Kuppusamy UR; Tan JA
West Indian Med J; 2011 Jan; 60(1):3-8. PubMed ID: 21809703
[TBL] [Abstract][Full Text] [Related]
4. Endocrinopathies, metabolic disorders, and iron overload in major and intermedia thalassemia: serum ferritin as diagnostic and predictive marker associated with liver and cardiac T2* MRI assessment.
Chirico V; Rigoli L; Lacquaniti A; Salpietro V; Piraino B; Amorini M; Salpietro C; Arrigo T
Eur J Haematol; 2015 May; 94(5):404-12. PubMed ID: 25200112
[TBL] [Abstract][Full Text] [Related]
5. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
Ha SY; Mok AS; Chu WC; Raskalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
Hemoglobin; 2009; 33(5):323-31. PubMed ID: 19814678
[TBL] [Abstract][Full Text] [Related]
6. Total antioxidant capacity and ischemia modified albumin in beta thalassemia.
Awadallah S; Al Arrayed K; Bahareth E; Saeed Z
Clin Lab; 2013; 59(5-6):687-91. PubMed ID: 23865371
[TBL] [Abstract][Full Text] [Related]
7. Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience.
Abdelrazik N
Hematology; 2007 Dec; 12(6):577-85. PubMed ID: 17852442
[TBL] [Abstract][Full Text] [Related]
8. The effect of aqueous extract of Iranian oak (Quercus brantii) on antioxidant capacity and oxidative stress in beta-thalassemia patients: Randomized controlled trial.
Babamir Satehi M; Karimi M; Farrokhian Z; Pakbaz F
Clin Nutr ESPEN; 2024 Jun; 61():230-236. PubMed ID: 38777439
[TBL] [Abstract][Full Text] [Related]
9. N-Acetylcysteine supplementation reduces oxidative stress and DNA damage in children with β-thalassemia.
Ozdemir ZC; Koc A; Aycicek A; Kocyigit A
Hemoglobin; 2014; 38(5):359-64. PubMed ID: 25222041
[TBL] [Abstract][Full Text] [Related]
10. Study of Serum Immunoglobulin Levels and T lymphocyte Subsets in Children with Beta Thalassemia with Iron Overload in Egypt.
Hagag AA; Elgamasy MA; Abd Elbar ES
Egypt J Immunol; 2016 Jan; 23(1):97-105. PubMed ID: 28502157
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy - deferasirox and deferoxamine - in thalassemia major patients in emerging countries with limited resources.
Arandi N; Haghpanah S; Safaei S; Zahedi Z; Ashrafi A; Eatemadfar P; Zarei T; Radwan AH; Taher AT; Karimi M
Transfus Med; 2015 Feb; 25(1):8-12. PubMed ID: 25801075
[TBL] [Abstract][Full Text] [Related]
12. Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy.
Chirico V; Lacquaniti A; Salpietro V; Luca N; Ferraù V; Piraino B; Rigoli L; Salpietro C; Arrigo T
Eur J Endocrinol; 2013 Dec; 169(6):785-93. PubMed ID: 24014554
[TBL] [Abstract][Full Text] [Related]
13. The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients.
Mirbehbahani N; Jahazi A; Rahim Abad HH
Hematology; 2012 May; 17(3):183-6. PubMed ID: 22664119
[TBL] [Abstract][Full Text] [Related]
14. Thalassemia major patients using iron chelators showed a reduced plasma thioredoxin level and reduced thioredoxin reductase activity, despite elevated oxidative stress.
Ozturk Z; Genc GE; Kupesiz A; Kurtoglu E; Gumuslu S
Free Radic Res; 2015 Mar; 49(3):309-16. PubMed ID: 25564095
[TBL] [Abstract][Full Text] [Related]
15. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
Shalitin S; Carmi D; Weintrob N; Phillip M; Miskin H; Kornreich L; Zilber R; Yaniv I; Tamary H
Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
[TBL] [Abstract][Full Text] [Related]
16. A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine.
Moayedi B; Gharagozloo M; Esmaeil N; Maracy MR; Hoorfar H; Jalaeikar M
Eur J Haematol; 2013 Mar; 90(3):202-9. PubMed ID: 23278124
[TBL] [Abstract][Full Text] [Related]
17. Increased oxidative stress and iron overload in Jordanian β-thalassemic children.
Abdalla MY; Fawzi M; Al-Maloul SR; El-Banna N; Tayyem RF; Ahmad IM
Hemoglobin; 2011; 35(1):67-79. PubMed ID: 21250883
[TBL] [Abstract][Full Text] [Related]
18. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
Tsironi M; Assimakopoulos G; Polonofi K; Rigaki K; Aessopos A
Hemoglobin; 2008; 32(1-2):29-34. PubMed ID: 18274980
[TBL] [Abstract][Full Text] [Related]
19. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
[TBL] [Abstract][Full Text] [Related]
20. Correlation of iron overload and glomerular filtration rate estimated by cystatin C in patients with β-thalassemia major.
Al-Khabori M; Bhandari S; Al-Rasadi K; Mevada S; Al-Dhuhli H; Al-Kemyani N; Daar S
Hemoglobin; 2014; 38(5):365-8. PubMed ID: 25074643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
